Article

Efficacy and safety analysis of PARP inhibitors combined with drugs for primary and relapsed ovarian cancer: A meta-analysis of randomized controlled trials

2022-07-18

Abstract excerpt

<h4>Background: </h4> Poly ADP-ribose polymerase (PARP) inhibitors have emerged as maintenance therapy for advanced ovarian cancer. However, due to the development of drug resistance, combination of PARP inhibitors with other chemotherapeutic agents has become a contemporary research hotspot. <h4>Methods:</h4> We conducted a meta-analysis of phase II or III randomized controlled trials to analyze the efficacy and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7431bfcd-e39d-51fa-aaf2-e598f8a1d051
DOI: 10.22541/au.165815731.18631635/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety analysis of PARP inhibitors combined with drugs for primary and relapsed ovarian cancer: A meta-analysis of randomized controlled trialsDOI 10.22541/au.165815731.18631635/v1Read

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.Semantic proximity Read

Perspectives on PARP Inhibitor Combinations for Ovarian CancerSemantic proximity Read

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancerSemantic proximity Read

Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: An updated systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?Semantic proximity Read

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersSemantic proximity Read

PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian CancerSemantic proximity Read

PARP inhibitors: a tsunami of indications in different malignancies.Semantic proximity Read